DNA vaccination of neonate piglets in the face of maternal immunity induces humoral memory and protection against a virulent pseudorabies virus challenge.
DNA vaccination represents a unique opportunity to overcome the limitations of conventional vaccine strategy in early life in the face of maternal-derived immunity. We used the model of pseudorabies virus (PRV) infection in pigs to further explore the potential of DNA vaccination in piglets born to sows repeatedly vaccinated with a PRV inactivated vaccine. A single immunisation of 8-week-old piglets with a DNA vaccine expressing secreted forms of PRV gB, gC, and gD, triggered an active serological response, confirming that DNA vaccination can over-ride significant residual maternal-derived immunity. A clear anamnestic response was evidenced when a secondary DNA vaccination was performed at 11 weeks of age, suggesting that DNA vaccination, performed in the face of passive immunity, elicited a strong humoral memory. We subsequently explored the potential of DNA vaccination in neonate piglets (5-6 days of age) in the face of very high titres of maternal antibodies and demonstrated that very high titres of passive antibodies selectively inhibited serological responses but not the establishment of potent memory responses. Finally, we demonstrated that DNA vaccination provided protection against an infectious PRV challenge at the end of the fattening period (i.e. at approximately 5 months of age). Collectively, our results pave the way for a new flexible vaccination program, which could ensure uninterrupted protection of fattening pigs over their entire economical life under field conditions.
Fischer
Laurent
L
Merial SAS, Biological Discovery Research, 254 rue Marcel Mérieux, 69007, Lyon, France. laurent.fischer@merial.com
Barzu
Simona
S
Andreoni
Christine
C
Buisson
Nathalie
N
Brun
André
A
Audonnet
Jean Christophe
JC
D000818:Animals; D000831:Animals, Newborn; D000917:Antibody Formation / Q000276:immunology; D016466:CHO Cells; D006224:Cricetinae; D005260:Female; D011558:Herpesvirus 1, Suid / Q000276:immunology* / Q000472:pathogenicity*; D007112:Immunity, Maternally-Acquired / Q000276:immunology*; D011557:Pseudorabies / Q000276:immunology / Q000517:prevention & control*; D013552:Swine; D019444:Vaccines, DNA / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D014774:Virulence
D019444:Vaccines, DNA